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Multiple Sclerosis
Michelle Summers, RN, BSN
Otterbein University, Westerville, Ohio
What is Multiple
Sclerosis?
Multiple Sclerosis (MS) is an
idiopathic, chronic, auto-immune,
inflammatory disease of the central
nervous system (Balto et al., 2017).
First discovered over 150 years ago,
MS is now the most common chronic
inflammatory disease affecting the
central nervous system (CNS).
Affected individuals now make up a
group of over 2 million people across
the globe, with at least 400,00 of
those affected being Americans
(Reich, Lucchinetti, & Calabresi, 2018)
. MS is characterized by recurrent
events of inflammation in the CNS,
resulting in demyelination and
damage to axons in the brain, spinal
cord, and various nerves throughout
the CNS, namely the optic nerve
(Bishop & Rumrill, 2015). Due to the
chronic nature of the disease, with its
unpredictable and intermittent
demyelination episodes, MS is a
known prevalent cause of disability
and loss of function in young to
middle-aged adults (Zostawa,
Adamczyk, Sowa, & Adamczyk-Sowa,
2017).

Pathophysiology of MS
MS affects both the gray and white matter of the CNS. It is a chronic, and
progressive auto-immune disease with no known cause at present (Herranz et
al., 2016). There are thought to be some genetic and modifiable factors to the
development of MS, including obesity, smoking, sedentary lifestyle, high sodium
intake, and low vitamin D levels. Females make up approximately three times
the number of males affected by MS. There also appears to be a connection
between the development of MS and the Epstein-Barr Virus (EBV), with almost
all patients with MS having a history of EBV infection (Zostawa et al., 2017).
The process in which demyelination occurs and plaque is formed is complex.
The process involves activated T and B immune cells that cause inflammation to
occur through the wrongful recognition of autoantigens from the myelin (Fard,
2016). Through auto-immune responses, the myelin sheaths are destroyed by
attacks from the activated T cells. Myelin in a neuron covering that aids in the
facilitation of axonal conduction of signals between the brain and other parts of
the body through the spinal cord. With the destruction of myelin sheaths, the
communication between brain and body is affected, causing the messages to not
be sent or received effectively or correctly. The damaged myelin is then replaced
with areas of scar tissue with subsequent plaque formation, further damaging
nerve conduction (Bishop & Rumrill, 2015).

Significance of Pathophysiology
Though somewhat understood how MS occurs through the destruction of myelin and
subsequent plaque formation and loss of function, there is still much to be
understood about who MS affects, when, and why, especially in regards to how the
disease progresses in each individual. It is unknown whether MS has a multitude of
causes or one single, specific trigger for development, though most research points
to various factors.
•

•

There have been more than 200 gene variants that increase the risk of MS, and
a two to four percent risk for development in those with a first degree relative
with MS (Reich et al., 2018).

•

As a progressive disease, relapse and exacerbations are common throughout
the chronic disease course. Whether lesions will continue to grow and form into
plaques, or even remyelinate is still not understood (Reich et al., 2018).

•

During an MS relapse, demyelination and axonal transection can and do occur,
which can lead to permanent disability. Further demyelination leads to
increased lesions in number or in size, and subsequent greater amounts of
plaque formation, further progressing the neurologic dysfunction (Sevim,
2016).

•

Prognosis of MS is largely related to the frequency of relapses. The higher the
relapse occurrence in the first five years, and the areas of involvement, such as
the spinal cord or brain stem, are indicators of a poorer prognosis than those
with few relapses (Sevim, 2016).

•

There are four major types of MS that can help to classify and predict the
clinical course of MS. The most common is relapsing-remitting (RRMS), which
affects roughly 85% of newly diagnosed individuals. RRMS can progress to
secondary-progressive MS (SPMS). It occurs in about 50% of RRMS patients,
and shows worsening neurologic dysfunction . The remaining 10-15% of initial
MS cases are considered primary-progressive (PPMS). In PPMS, neurologic
dysfunction symptoms appear at time of diagnosis, but there are no periods of
relapse or remission., just worsening function. 5% or less of initial MS
diagnoses are progressive-relapsing (RPMS). This Is similar to PPMS, but with
periods of relapse and remission (Visaria, Thomas, Gu, Singer, & Tan, 2018).

Topic Selection
The topic of MS was selected out of
a place of hope and fear. I come
from a family with an unfortunately
thick history of Multiple Sclerosis,
with a paternal grandfather, two
great uncles, as well as my own
mother who have suffered, or are
still suffering from the disease.
Though my mother has luckily been
in remission for ten years, the rest
of my family has not been as
fortunate. Their diagnoses and
struggles, as well as my fear of
even a slight genetic link pushes
me to know as much as I can about
the disease for my family’s sake,
my sake, and for that of any future
patients who may also have this
chronic disease. I have hope that
with the continuing research that
we will better understand the
cause of MS, and with that, know
better prevention strategies, and
even a cure.
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Signs and Symptoms
Due to the progressive destruction of myelin and the formation of plaque, the
patient will develop various signs and symptoms related to the areas of
specific nerve damage. These signs and symptoms include:
•
Pain- more than 75% of MS patients report that pain is their most
significant symptom. This pain includes central neuropathic pain,
musculoskeletal pain, and headaches (Senders, Borgatti, Hanes, & Shinto,
2018).
•
Cognitive disfunction, including memory loss affects up to 50% of
individuals with MS (Fritz et al., 2016).
•
Vision loss- monocular vision loss from optic neuritis, double vision loss
from brainstem plaque ( Reich et al., 2018).
•
Limb ataxia, limb weakness, and sensory loss due to transverse myelitis
or lesions on the cerebellum (Reich et al., 2018).
•
Progressive neurologic deterioration hallmarked by ambulation
impairment and loss of continence (Reich et al., 2018).

Women, especially women of childbearing age, are the most likely to be
diagnosed with MS than their male counterparts, suggesting there may be a
hormonal factor to MS development (Bishop & Rumrill, 2015). The frequency of
relapse can also increase in the first three month post partum, also indicating
that there may be a hormonal factor. Relapses are also more likely to occur
during times of stress, both physical and psychological (Sevim, 2016).

Diagnostics
A diagnosis of MS can be made one of two ways. The first, though rarely
done, is through directly sampling the CNS tissue through a biopsy. The CNS
tissue may produce biomarkers that can aid in the diagnosis and prognosis of
MS. The most commonly utilized, and most reliable for early diagnosis of MS
is through magnetic resonance imaging (MRI). With an MRI, the diagnostic
team can see the entirety of the CNS and visualize any demyelination (Reich et
al., 2018).
.

Nursing Implications
As a chronic, progressive, neurologic disease, the role of the nurse is
very important is disease management and education, and support.
Though no cure exists, there are 15 approved medications for disease
management as of December 2017 (Reich et al., 2018). The role of the
nurse in disease management is seen by educating the patient on the
importance of taking the disease-modifying therapies (DMTs) as
prescribed even when signs or symptoms may not be present, or
when the patient does not feel any improvement. The first line of
DMTs are self injectable, and have a low rate of compliance, leading to
further dysfunction development (Visaria, et al, 2018).
MS patients also need the support of nurses throughout the course of
their disease. As a disease primarily being diagnosed in early
adulthood, what are supposed to be the most productive years of life,
MS patients may feel uncertainty and fear regarding their diagnosis.
They may feel shame as their body starts to weaken, feels foreign, or
if they lose control of bladder and bowel. Their dignity is hurt
through the disease process, but the nurse is able to support the
patient through active listening, reassurance, and the ability to
answer any questions the patient may have.
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Conclusion
To conclude, MS is a chronic, autoimmune, inflammatory disease of
the CNS that leads to neurological dysfunction. The pathophysiology
involves activated T cells wrongly attacking and destroying the myelin
sheaths of neurons which aid in the conduction of signals between brain
and body. Damaged myelin is replaced with scar tissue which can form
into plaques, further damaging the routes of communication between
brain and body. This process leads to the development of neurologic
dysfunction of the affected nerves. Primarily affecting females in the
early to middle adulthood, the disease’s prognosis is related to the
number of relapses and how rapid the disease progresses. No one single
cause has yet been identified in MS, but risk factors include gender,
obesity, tobacco abuse, low vitamin D levels, as well as over 200 genetic
variants that can increase the risk of development. There currently is no
cure, so treatment is based on disease modification and maintenance,
and the prevention of relapse.
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